Exhibit 99.1 Genmab Announces Financial Results for the First Nine Months of 2022 November 9, 2022 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2022 Highlights "During the first nine months of the year we continued to build on Genmab's consistent track record of success. We have strengthened our pipeline, our team and our financial foundation is even more robust. We are pleased with the recent U.S. and European regulatory submissions for epcoritamab. These submissions ar ...

Genmab A/S (GMAB) Q2 2022 Results Conference Call August 10, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Anthony Mancini - COO Tahi Ahmadi - Chief Medical Officer Conference Call Participants Wimal Kapadia - Bernstein Jonathan Chang - SVB Sachin Jain - Bank of America Asthika Goonewardene - Truist Securities James Gordon - JP Morgan Paul Jeng - Guggenheim Securities Elizabeth Walton - Credit Suisse Zoe Karamano ...

Exhibit 99.1 Genmab Announces Financial Results for the First Half of 2022 August 10, 2022 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022 Highlights "Genmab's innovation was on display during the second quarter of 2022 with data presentations at multiple prestigious conferences and the publication by Genmab, and our partner, AbbVie, of topline results for epcoritamab from the Phase 1/2 trial in patients with relapsed/refractory LBCL. Based on this data, we intend to submit ...

Quarter End Results Period Ended March 31, 2022 Forward looking statement This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development ...

Genmab A/S (GMAB) Q1 2022 Earning Conference Call May 11, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Peter Virgil - Citigroup James Gordon - JPMorgan Wimal Kapadia - Bernstein Peter Welford - Jefferies Michael Schmidt - Guggenheim Securities Asthika Goonewardene - Truist Securities Xian Deng - Berenberg Charlie Yang - Morgan Stanley Yaron Werber - Cowen & Co. Operator Hello, and welcome ...

Exhibit 99.1 Genmab Announces Financial Results for the First Quarter of 2022 May 11, 2022 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022 ● Net sales of DARZALEX by Janssen were USD 1,856 million in the first three months of 2022 compared to USD 1,365 million in the first three months of 2021, an increase of USD 491 million, or 36%. ● Royalty revenue was DKK 1,836 million in the first three months of 2022 compared to DKK 1,017 million in the first three months of 2021, an inc ...

Year End Results Period Ended December 31, 2021 Forward looking statement This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development ...

Genmab A/S (GMAB) Q4 2021 Earnings Conference Call February 16, 2022 12:00 PM ET Company Participants Jan van de Winkel – President and Chief Executive Officer Anthony Pagano – Chief Financial Officer Anthony Mancini – Chief Operation Officer Tahi Ahmadi – Chief Medical Officer Conference Call Participants Wimal Kapadia – Bernstein James Gordon – JP Morgan Kennen MacKay – RBC Paul – Guggenheim Securities Elizabeth Walton – Credit Suisse Peter Virgil – Citi Asthika Goonewardene – Truist Securities Peter Welf ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ◻ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 1 ...

GENMAB 2021 ANNUAL REPORT Table of Contents Using Science to Turn Insights into Medicine | MANAGEMENT'S REVIEW | | | --- | --- | | About Genmab | 3 | | Who We Are | 3 | | Timeline | 5 | | 2021 at a Glance | 6 | | Our World-class Team | 7 | | Commercialization | 8 | | Chair's Statement | 9 | | Letter from the CEO | 11 | | Consolidated Key Figures | 13 | | 2022 Outlook | 15 | | Business Model | 16 | | Our Strategy | 18 | | Our Business | 20 | | Research and Development Capabilities | 20 | | Antibody Discovery ...